{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T20:32:48Z","timestamp":1782937968990,"version":"3.54.5"},"reference-count":34,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T00:00:00Z","timestamp":1616025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/501100001704","name":"European Society of Clinical Microbiology and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001704","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2021,3,18]]},"abstract":"<jats:p>\n            Posaconazole is more active than fluconazole against\n            <jats:named-content content-type=\"genus-species\">Candida albicans<\/jats:named-content>\n            <jats:italic>in vitro<\/jats:italic>\n            and is approved for the treatment of oropharyngeal candidiasis but not for that of invasive candidiasis (IC). Here, we explored the efficacy of posaconazole against\n            <jats:named-content content-type=\"genus-species\">C. albicans<\/jats:named-content>\n            in an\n            <jats:italic>in vitro<\/jats:italic>\n            pharmacokinetic\/pharmacodynamic (PK\/PD) model of IC and determined the probability of pharmacodynamic target attainment for the oral solution and intravenous (i.v.)\/tablet formulations.\n          <\/jats:p>","DOI":"10.1128\/aac.01292-20","type":"journal-article","created":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T12:53:17Z","timestamp":1610974397000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":9,"title":["The Role of New Posaconazole Formulations in the Treatment of Candida albicans Infections: Data from an\n            <i>In Vitro<\/i>\n            Pharmacokinetic-Pharmacodynamic Model"],"prefix":"10.1128","volume":"65","author":[{"given":"Maria-Ioanna","family":"Beredaki","sequence":"first","affiliation":[{"name":"Clinical Microbiology Laboratory, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4747-0144","authenticated-orcid":true,"given":"Maiken Cavling","family":"Arendrup","sequence":"additional","affiliation":[{"name":"Unit of Mycology, Statens Serum Institut, Copenhagen, Denmark"},{"name":"Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark"},{"name":"Department of Clinical Microbiology, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7927-9950","authenticated-orcid":true,"given":"David","family":"Andes","sequence":"additional","affiliation":[{"name":"University of Wisconsin, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan W.","family":"Mouton","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, Erasmus Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8869-1509","authenticated-orcid":true,"given":"Joseph","family":"Meletiadis","sequence":"additional","affiliation":[{"name":"Clinical Microbiology Laboratory, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece"},{"name":"Department of Medical Microbiology and Infectious Diseases, Erasmus Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03646.x"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00163-06"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2003.09.008"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00937-12"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh027"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0507.2011.02061.x"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03050-14"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02686-13"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.48.1.137-142.2004"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz425"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00170-20"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm350"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.2.638-642.2005"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.12579"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit358"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2004.06.002"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.9.2116"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.47.10.3165-3169.2003"},{"key":"e_1_3_3_20_2","unstructured":"EUCAST. 2013. Fluconazole: rationale for the EUCAST clinical breakpoints version 2.0. http:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Rationale_documents\/Fluconazole_rationale_2_0_20130223.pdf."},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03712.x"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/imj.12600"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02441-10"},{"key":"e_1_3_3_24_2","unstructured":"European Medicines Agency Committee for Medicinal Products for Human Use. 2014. Assessment report noxafil. EMA\/159150\/2014. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Assessment_Report_-_Variation\/human\/000610\/WC500168187.pdf."},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1086\/504810"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12281-016-0255-4"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1086\/501457"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1086\/511039"},{"key":"e_1_3_3_29_2","volume-title":"Performance standards for antifungal susceptibility testing of yeasts","author":"Clinical and Laboratory Standards Institute","year":"2017","unstructured":"Clinical and Laboratory Standards Institute. 2017. Performance standards for antifungal susceptibility testing of yeasts. CLSI supplement M60, 1st ed. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"1"},{"key":"e_1_3_3_30_2","unstructured":"Arendrup MC Meletiadis J Mouton JW Lagrou K Hamal P Guinea j the Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST). 2020. EUCAST definitive document E.Def 7.3.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts."},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00662-11"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.2.658-666.2006"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01671-10"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02615-13"},{"key":"e_1_3_3_35_2","unstructured":"EUCAST. 2020 Posaconazole rationale document for EUCAST clinical breakpoints version 3.0."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01292-20","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01292-20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T23:37:58Z","timestamp":1645486678000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01292-20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,18]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,3,18]]}},"alternative-id":["10.1128\/AAC.01292-20"],"URL":"https:\/\/doi.org\/10.1128\/aac.01292-20","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,18]]},"assertion":[{"value":"2020-06-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01292-20"}}